Skip to main content
. 2022 Jan 17;9(1):e001157. doi: 10.1136/bmjresp-2021-001157

Table 3.

Summary of responses from each Australian institution identified as managing lung cancer patients, stratified by high (100) or low (≤99) annual case volume

Annual cases n/N (%)
Low (≤99) High (100)
Total no institutions† 23 55
Public 15/23 (65.2) 49/55 (89.1)
Private 8/23 (34.8)* 6/55 (10.9)
Metropolitan 12/23 (52.2) 42/55 (76.4)
Regional 11/23 (47.8) 13/55 (23.6)
Has regular MDT 19/23 (82.6) 54/55 (98.2)
No regular MDT 4/23 (17.4) 1/55 (1.8)
Frequency of MDT
Weekly 7/18 (38.9) 42/53 (76.4)
Fortnightly 11/18 (47.8)* 11/53 (20.0)
EBUS on site 8/23 (34.8) 50/55 (90.9)
Medical oncology on site 20/23 (87.0) 53/55 (96.4)
Radiation oncology on site 14/23 (60.9) 42/55 (76.4)
Specialist lung cancer nurse on site 6/22 (27.3)* 33/53 (62.3)
If yes FTE (median) 0.5 0.8
Core MDT members per OCP guidelines 8/21 (38.1) 34/53 (64.2)
Full recommended MDT attendance per OCP guidelines 0/21 0/53
QA against National guidelines
 None 7/17 (41.2) 9/53 (16.4)
 Very infrequent 3/17 (17.6) 12/53 (22.6)
 Yes, ad hoc 4/17 (23.5) 9/53 (17.0)
 Yes, regularly 3/17 (17.6) 23/53 (43.3)

All data presented as n (%).

*P<0.05, compared with high volume.

†The denominator for responses varied as not all questions were answered by every respondent.

EBUS, endobronchial ultrasound; FTE, (fraction of) full time equivalent; MDT, multidisciplinary team; OCP, Optimal Care Pathway; QA, quality assurance.